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A knowledge-based systems biotechnology approach integrates multiomics data and genome-scale model to characterize the cellular transfection of a Chinese hamster ovary cell line, thereby identifying key engineering targets for cell-line development and engineering. 
SUMMARY
Effective development of host cells for therapeutic protein production is hampered by the poor characterization of cellular transfection. Here, we employed a multi-omics-based systems biotechnology approach to elucidate the genotypic and phenotypic differences between a wild-type and recombinant antibody-producing Chinese hamster ovary (CHO) cell line. At the genomic level, we observed extensive rearrangements in specific targeted loci linked to transgene integration sites. Transcriptional re-wiring of DNA damage repair and cellular metabolism in the antibody producer, via changes in gene copy numbers, was also detected. Subsequent integration of transcriptomic data with a genome-scale metabolic model showed a substantial increase in energy metabolism in the antibody producer. Metabolomics, lipidomics, and glycomics analyses revealed an elevation in long-chain lipid species, potentially associated with protein transport and secretion requirements, and a surprising stability of N-glycosylation profiles between both cell lines. Overall, the proposed knowledge-based systems biotechnology framework can further accelerate mammalian cell-line engineering in a targeted manner.
INTRODUCTION
Chinese hamster ovary (CHO) cell lines are the biopharmaceutical industry's workhorses as they can carry out complex posttranslational modifications (e.g., human-like N-glycosylation) on proteins, satisfying the required therapeutic activity. The dramatic increase in productivity and titer of CHO cells achieved via various bioprocess optimizations (Jayapal et al., 2007) has now made them the most widely used cell factory for biopharmaceutical production: 7 of the top 10 drugs, including monoclonal antibodies (mAbs), are now being produced using CHO cells (Walsh, 2014) . However, although overall yields from mammalian cells have increased up to 100-fold over the decades (Wurm, 2004) , the corresponding per-cell yields have not been improved substantially (Carinhas et al., 2012) . Much of this progress has been made through advancements in cell-culture processes and media compositions, with comparatively little development in characterizing and exploiting cell-culture biology. In this sense, the current advances in omics technologies allow for a more in-depth understanding of CHO cell physiology (Datta et al., 2013; Farrell et al., 2014; Kildegaard et al., 2013) . Moreover, the recent availability of various CHO cell-line genomes (Brinkrolf et al., 2013; Kaas et al., 2015; Lewis et al., 2013; Xu et al., 2011) can facilitate the use of systems approaches for better characterizing and engineering.
Over the last decade, numerous studies have adopted highthroughput omics-based approaches to elucidate CHO cell physiology and regulation. For example, several transcriptomic and proteomic studies have explored the relationship between gene expression and high productivity under varying culture conditions (Baik et al., 2006; Bedoya-Ló pez et al., 2016) , differing productivity levels (Charaniya et al., 2009; Schaub et al., 2010; Yee et al., 2009) , and upon inducer treatments (Fomina-Yadlin et al., 2015; Kantardjieff et al., 2010) . Similarly, mass-spectrometry-based metabolomics profiling has been applied to identify nutrient limitations (Sellick et al., 2011) , find apoptosis-inducing metabolites (Chong et al., 2011) and link metabolites with growth rates and productivity (Chong et al., 2012; Wilkens and Gerdtzen, 2015) . Furthermore, renewed and
